Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Promising Cellular Immunotherapy for Colorectal Cancer Using Classical Dendritic Cells and Natural Killer T Cells

Title: Promising Cellular Immunotherapy for Colorectal Cancer Using Classical Dendritic Cells and Natural Killer T Cells
Authors: Singer, Mahmoud; Valerin, Jennifer; Zhang, Zhuoli; Zhang, Zigeng; Dayyani, Farshid; Yaghmai, Vahid; Choi, April; Imagawa, David; Abi-Jaoudeh, Nadine
Source: Cells, vol 14, iss 3
Publisher Information: eScholarship, University of California
Publication Year: 2025
Collection: University of California: eScholarship
Subject Terms: 32 Biomedical and Clinical Sciences (for-2020); 3211 Oncology and Carcinogenesis (for-2020); 3204 Immunology (for-2020); Women's Health (rcdc); Immunotherapy (rcdc); Immunization (rcdc); Digestive Diseases (rcdc); Colo-Rectal Cancer (rcdc); Vaccine Related (rcdc); Cancer (rcdc); 5.1 Pharmaceuticals (hrcs-rac); Cancer (hrcs-hc); 3 Good Health and Well Being (sdg); Humans (mesh); Colorectal Neoplasms (mesh); Dendritic Cells (mesh); Immunotherapy (mesh); Natural Killer T-Cells (mesh); Animals (mesh); Tumor Microenvironment (mesh); colorectal cancer; CRC; classical dendritic cells; NKT cells; NK cells; tumor microenvironment; TME modulation; cellular immunotherapy
Subject Geographic: 166 - 166
Description: Colorectal cancer (CRC) remains one of the leading causes of cancer-related morbidity and mortality around the world. Despite advances in surgery, chemotherapy, and targeted therapies, the prognosis for patients with metastatic or advanced CRC remains poor. Immunotherapies comprising immune checkpoint inhibitors showed disappointing responses in metastatic CRC (mCRC). However, cellular immunotherapy, specifically using classical dendritic cells (cDCs), may hold unique promise in immune recognition for CRC antigens. cDCs are substantial players in immune recognition and are instrumental in orchestrating innate and adaptive immune responses by processing and presenting tumor antigens to effector cells. Natural killer T (NKT) cells are insufficiently studied but unique effector cells because of their ability to bridge innate and adaptive immune reactions and the crosstalk with dendritic cells in cancer. This review explores the therapeutic potential of using both cDCs and NKT cells as a synergistic therapy in CRC, focusing on their biological roles, strategies for harnessing their capabilities, clinical applications, and the challenges within the tumor microenvironment. Both cDCs and NKT cells can be used as a new effective approach for cell-based therapies in cancers to provide a new hope for CRC patients that are challenging to treat.
Document Type: article in journal/newspaper
File Description: application/pdf
Language: unknown
Relation: qt6jh1m327; https://escholarship.org/uc/item/6jh1m327; https://escholarship.org/content/qt6jh1m327/qt6jh1m327.pdf
DOI: 10.3390/cells14030166
Availability: https://escholarship.org/uc/item/6jh1m327; https://escholarship.org/content/qt6jh1m327/qt6jh1m327.pdf; https://doi.org/10.3390/cells14030166
Rights: CC-BY
Accession Number: edsbas.8CD8B6DA
Database: BASE